AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?

Eli Lilly generated FY2025 revenue of about $65.2 billion (+45% year over year) and net income of $20.6 billion (32% margin), with 2026 sales projected to rise roughly 30% to $85.2 billion on continued Zepbound and Mounjaro demand. AbbVie posted FY2025 revenue of $61.2 billion (+9%) and $4.3 billion of net income, but is projected to reach $67.2 billion in sales and $14.6 billion in net income as Skyrizi, Rinvoq, pipeline assets and the Apogee Therapeutics acquisition offset legacy-drug exclusivity losses. Lilly offers faster growth but trades at higher valuations (24.8x forward P/E and 13.2x P/S) versus AbbVie (16.4x and 7.3x), which the article favors as the more value-oriented long-term purchase.

Analysis

The relevant relative-value question is not growth versus value, but how much execution is already capitalized in LLY versus how much immunology durability is discounted in ABBV. LLY's obesity franchise needs sustained volume growth, manufacturing expansion, payer access and limited price erosion simultaneously; even modest gross-to-net deterioration can matter disproportionately at a premium sales multiple. ABBV's earnings inflection is more sensitive to the pace at which Skyrizi/Rinvoq replace legacy erosion and to post-acquisition R&D discipline, but its higher free-cash-flow conversion provides a cushion absent from headline net-income comparisons distorted by acquisition accounting and amortization.

Over the next 1-3 months, formulary decisions, supply commentary and competitor trial data are more likely to move LLY than broad obesity-demand optimism. CVS and other PBMs have incentive to use coverage restrictions and competing GLP-1 supply to capture rebates; that is a margin risk for LLY but a potential volume/working-capital tailwind for wholesalers MCK and COR as branded specialty-drug throughput rises. For ABBV, the more material near-term catalyst is evidence that immunology share gains remain intact despite biosimilar and payer pressure, rather than a binary pipeline headline.

The contrarian setup is that LLY may be more vulnerable to a valuation reset than to an earnings miss: decelerating growth from an exceptional base can compress the multiple even with strong absolute results. Conversely, ABBV's apparent balance-sheet leverage is less informative than net debt/FCF and debt-maturity capacity; the thesis fails if immunology growth slows before legacy erosion abates or if acquisition-related spending materially weakens cash returns. A defensive healthcare allocation should therefore favor cash-flow durability while retaining only defined-risk exposure to LLY's obesity upside.

Key Decisions for Investors

• Initiate a 6-12 month pair: long ABBV / short LLY in equal dollar beta-adjusted weights. Target 10-15% relative return from ABBV multiple resilience plus LLY growth/multiple normalization; stop if LLY raises forward revenue guidance by more than 10% while ABBV cuts immunology guidance or reports sequential Skyrizi/Rinvoq share loss.
• For existing LLY longs, replace part of outright exposure with a 3-6 month collar around the next earnings and payer-update window. The key watch item is realized net price/gross-to-net commentary rather than prescription demand; maintain upside participation but protect against a 15-20% premium-multiple drawdown.
• Add MCK or COR selectively on weakness as indirect GLP-1 volume beneficiaries, preferring MCK for diversified specialty distribution exposure. Size modestly: distributor economics depend on fee structure and working capital, so do not underwrite a direct pass-through of drug price inflation.
• Do not chase APGE on ABBV acquisition-readthrough without transaction terms, pro forma dilution and development timelines. Set an alert for disclosed consideration and ABBV's updated capital-allocation framework; recommend only if expected risk-adjusted pipeline value exceeds dilution and ABBV preserves debt-reduction capacity.